Sentry Investment Management LLC Sells 3,328 Shares of DexCom, Inc. (NASDAQ:DXCM)

Sentry Investment Management LLC lessened its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 64.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,874 shares of the medical device company’s stock after selling 3,328 shares during the period. Sentry Investment Management LLC’s holdings in DexCom were worth $126,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Team Hewins LLC lifted its stake in DexCom by 3.4% in the first quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock valued at $354,000 after buying an additional 83 shares in the last quarter. Bleakley Financial Group LLC lifted its position in DexCom by 1.3% in the 1st quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock valued at $951,000 after acquiring an additional 87 shares in the last quarter. Capital Insight Partners LLC boosted its stake in DexCom by 2.5% in the 2nd quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock worth $418,000 after purchasing an additional 90 shares during the period. HM Payson & Co. increased its holdings in DexCom by 6.0% during the 1st quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock worth $247,000 after purchasing an additional 100 shares in the last quarter. Finally, Clear Creek Financial Management LLC raised its stake in shares of DexCom by 4.2% in the 2nd quarter. Clear Creek Financial Management LLC now owns 2,961 shares of the medical device company’s stock valued at $336,000 after purchasing an additional 120 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. UBS Group decreased their price objective on DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a report on Friday, July 26th. Leerink Partners lowered their price objective on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Wells Fargo & Company increased their target price on shares of DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, October 25th. Stifel Nicolaus lifted their price target on shares of DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, August 23rd. Finally, BTIG Research reduced their price objective on shares of DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and an average target price of $104.59.

DexCom Stock Down 1.0 %

Shares of NASDAQ:DXCM opened at $69.00 on Wednesday. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The firm has a market cap of $26.95 billion, a P/E ratio of 41.32, a P/E/G ratio of 2.16 and a beta of 1.17. The business has a fifty day simple moving average of $69.70 and a 200 day simple moving average of $94.48.

Insiders Place Their Bets

In other DexCom news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other DexCom news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by corporate insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.